Title of study

    Cerebral amyloid angioathy: vascular imaging and fluid biomarkers of amyloid deposition

    Acronym for cohort

    CAVIA

    Name of Principal Investigator - Title

    Dr

    Name of Principal Investigator - First name

    Marcel

    Name of Principal Investigator - Last name

    Verbeek

    Address of institution -Institution

    Radboudumc, Department of Neurology - 830 TML

    Address of institution - Street address

    PO Box 9101

    Address of institution - City

    Nijmegen

    Address of institution - Postcode

    6500 HB

    Country

    Netherlands

    Website
    Contact email
    Funding source

    ZonMW

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Alzheimer's disease and other dementias

    Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

    To identify novel biomarkers for Cerebral Amyloid Angiopathy, including body fluid (cerebrospinal fluid, blood) and imaging (MRI) biomarkers.

    Q2b. What distinguishes this case-control study from other studies?

    The focus on the identification of biomarkers for Cerebral Amyloid Angiopathy (CAA) is unique, but is very relevan since CAA occurs at high frequency in brains of eldely and AD patients and contributes to cognitive impairment.

    Q3a. i) Number of publications that involve use of your cohort to date

    4

    Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

    Description of novel body fluid and imaging biomarkers for hereditary and sporadic CAA

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

    50

    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    until death

    Q4b. Study criteria: what are the inclusion criteria?

    For CAA patients: Clinical diagnosis based on "Boston criteria". For memory clinic patients: no specific inclusion criteria, apart from availability of both CSF and MRI (T2* or SWI)

    Q4c. Study criteria: what are the exclusion criteria?

    No MRI or CSF available

    Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

    1-1,000

    Q5b. What is the expected number of control participants?

    200-500

    Q6a. Please describe what measures are used to characterise participants

    MRI and clinical / neurological examinations

    Q6b. Are there additional measures for participants with the clinical disorder?

    Boston criteria for CAA

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

    No

    If YES please specify

    Q7. What is the study design?

    Retrospective cohort| Cross sectional survey

    Q8. Are your cases matched by

    Age| Sex

    Q9a. Does your study includes a specialised subset of control participants?

    Yes

    Q9b. If your study includes a specialised subset of control participants please describe

    cases without history of neurological disease, but with CSF & MRI

    Q10a. Is data collection for this study

    Data collection ongoing| Data analysis ongoing

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - intend to apply for funding

    Q11. Are data collected

    Through links to medical records

    Q12. Is there a system in place to enable re-contact with patients for future studies?

    No

    Q13a. Please give information on data stored in a database (1)

    Data summarised in database

    % Available

    Q13a. Please give information on data stored in a database (2)

    Database is web-based

    % Available

    Q13a. Please give information on data stored in a database (3)

    No

    % Available

    Q13a. Please give information on data stored in a database (4)

    No

    % Available

    Q13a. Please give information on data stored in a database (5)

    No

    % Available

    Please specify language used

    % Available

    Q13b. Please give information on how data is held as individual records

    Data is web-based

    % Available

    Q14a. Are data available to other groups?

    Yes

    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Access through collaboration with PI only| Local/ regional access| National access| International access| Access to industry| Access for pilot studies permitted

    Q15. What data sharing policy is specified as a condition of use?

    No policy exists

    Q16a. Are tissues/samples/DNA available to other groups?

    Yes

    Q16b i) If yes, please describe below

    Living donors: blood| Living donors: cerebro-spinal fluid

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Primary Samples: Stabilised samples (frozen or fixed)

    Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Yes

    Q17. Is information on biological characteristics available to other groups?

    Yes, for all the cohort

Types: Case Control Studies
Member States: Netherlands
Diseases: Alzheimer's disease & other dementias
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF